Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug therapy in prediabetes.

Pradip Mukhopadhyay1, Subhankar Chowdhury

  • 1Department of Endocrinology and Metabolism, IPGME&R, Kolkata.

Journal of the Indian Medical Association
|March 31, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benefits Beyond Hypertension Control: Current and Evolving Treatment Strategies for Prevention of Cardiovascular Diseases.

Current hypertension reviews·2026
Same author

Integrated care for type 1 diabetes: The West Bengal model: 24-month follow-up.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Trabecular Bone Score and Bone Turnover Markers Unmask Early Skeletal Fragility in Children and Adolescents With Type 1 Diabetes.

AACE endocrinology and diabetes·2026
Same author

Female sexual dysfunction in type 1 diabetes: a systematic review and meta-analysis.

Endocrine·2026
Same author

Integrated multicompartment urinary long non-coding RNAs profiling (cellular, cell-free, and extracellular vesicle) for better differential diagnosis of biopsy-proven diabetic and non-diabetic kidney disease beyond conventional markers.

BMJ open diabetes research & care·2026
Same author

Sodium-Glucose Cotransporter 2 Inhibitors in Kidney Diseases Other Than That Due to Diabetes: Benefits in Composite Renal Outcomes Driven by Immunoglobulin A Nephropathy.

The Journal of the Association of Physicians of India·2026

Prediabetes, characterized by impaired fasting glucose and impaired glucose tolerance, significantly increases the risk of developing diabetes and cardiovascular diseases. Pharmacotherapy can improve glycemic status and potentially delay disease onset.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Cardiovascular Medicine

Background:

  • Prediabetes, encompassing impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), is a critical condition identified by the American Diabetes Association (ADA).
  • This condition signifies an elevated risk for both type 2 diabetes and atherosclerotic cardiovascular diseases.
  • Recognizing prediabetes is crucial due to its dual implications for long-term health outcomes.

Purpose of the Study:

  • To evaluate the role of pharmacotherapy in managing prediabetes.
  • To explore therapeutic strategies for preventing or delaying diabetes onset.
  • To assess the potential of medications in reducing cardiovascular complications associated with prediabetes.

Main Methods:

  • Review of existing literature on pharmacotherapy for prediabetes.

Related Experiment Videos

  • Analysis of studies investigating various drug classes, including metformin, glitazones, acarbose, orlistat, nateglinide, glicazide, ACE inhibitors, and ARBs.
  • Assessment of drug efficacy in improving glycemic control and reducing cardiovascular risk factors.

    • Main Results:

    • Several pharmacologic agents demonstrated efficacy in improving glycemic status in prediabetes patients.
    • Drugs evaluated include metformin, glitazones, acarbose, orlistat, nateglinide, glicazide, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers.
    • Despite demonstrated benefits, these medications are not currently recommended by professional organizations for prediabetes management.

    Conclusions:

    • Pharmacotherapy holds potential for managing prediabetes by improving glycemic control.
    • Interventions targeting prediabetes can aim to prevent or delay diabetes and mitigate cardiovascular risks.
    • Further research and guideline development are needed to establish a definitive role for pharmacotherapy in prediabetes treatment.